With effect from February 1, 2021, ExpreS2ion has recruited Dr. Mette Thorn as Vice President of Preclinical Development, and Dr. Lars J. Petersen as Medical Director, Oncology. From within, Dr. Max M. Søgaard will assume the position of Vice President, R&D and Technology. Furthermore, ExpreS2ion will refocus existing key roles in research and development and clinical planning/management. These organizational changes are made to facilitate the further advancement of the company’s pipeline development projects, with clinical trials planned within the next 1-2 years for COVID-19, breast cancer, influenza and malaria. Dr. Wian de Jongh, CSO & Co-Founder of ExpreS2ion, will now focus full-time on his role as CEO of AdaptVac and therefore leave his position as CSO of ExpreS2ion. At the same time, he will join a newly established Scientific Advisory Board that will advise ExpreS2ion in matters related to the company’s overall scientific direction. The organizational changes are thus implemented through a combination of recruitments and promotions of existing employees and consultants. The added personnel costs due to these changes are well within the financial planning set forth in the prospectus published in connection with ExpreS2ion’s oversubscribed rights issue that was conducted in October 2020.